West's Vial2Bag DC Device Receives FDA 510(k) Clearance and CE Mark
West Pharmaceutical Services has received 510(k) clearance of the Vial2Bag DC device from the FDA, and the CE Mark for the European Union.
The Vial2Bag DC device is produced by West's subsidiary, Medimop Medical Projects and is a universal admixture device designed to enable safe, convenient, needle-free reconstitution and transfer of drug products between a vial and a standard IV bag or bottle. The device connects to the IV bag set port using a standard IV spike and can be used with all standard manufacturers' bags. Following transfer of liquid from the bag, the reconstituted drug is then transferred from the vial back into the bag.
"Intravenous infusions are one of the most universally used methods of administration in healthcare settings. Our new Vial2Bag DC device simplifies the IV admixture process and eliminates the risk of needlestick injuries and minimises potential drug exposure, making this procedure safer and more efficient for healthcare staff," said John Paproski, President, Pharmaceutical Delivery Systems, West Pharmaceutical Services. "This 510(k) clearance and CE Marking extends West's leading portfolio of needle-free reconstitution and transfer devices and will complement the currently marketed Vial2Bag and Vial Adapter devices."
The device is available for 13-mm and 20-mm diameter vials, fits all standard IV bags and is ideal for point-of-care reconstitution and admixture and can assist in compliance with the immediate use provision of USP < 797 >. Progressive Medical Inc. (PMI) will distribute the Vial2Bag DC device to hospitals in the US.
"PMI is a leading distributor of specialty medical products that focuses on high-quality products that help improve patient safety and streamline hospital procedures. They have been successful with the Vial2Bag device over the past three years, which makes the company an excellent choice to distribute the innovative Vial2Bag DC device," said Mr Paproski.
Mark Martin, President and CEO of Progressive Medical Inc., said, "At PMI, our mission is to identify innovative new products that can improve the quality of patient healthcare, so we are very excited about the launch of Vial2Bag DC, because of its potential to improve patient outcomes, and at the same time, streamline and lessen costs in the healthcare system."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance